FY2027 EPS Estimates for MannKind Reduced by HC Wainwright

Key Points

• HC Wainwright cut its FY2027 EPS estimate for MannKind from $0.05 to $0.03 but kept a Buy rating with an $11.00 price target, and also projects FY2029 EPS of $0.16 and FY2030 EPS of $0.54.
• MannKind missed quarterly EPS expectations, reporting ($0.05) versus a ($0.01) consensus, while revenue grew 45.8% year‑over‑year to $111.96 million.
• CEO Michael Castagna bought 100,000 shares at $2.59 on March 10, increasing his holdings to 2,575,911 shares (a 4.04% rise), with insiders owning roughly 2.6% of the company.

MannKind Corporation (NASDAQ:MNKD - Free Report) - Equities research analysts at HC Wainwright cut their FY2027 earnings per share estimates for shares of MannKind in a report released on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will earn $0.03 per share for the year, down from their prior estimate of $0.05. HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for MannKind's current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for MannKind's FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.54 EPS.

MNKD has been the topic of several other research reports. Wells Fargo & Company lowered their price objective on shares of MannKind from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Friday, February 27th. Zacks Research upgraded shares of MannKind from a "strong sell" rating to a "hold" rating in a report on Wednesday, April 15th. Wedbush decreased their target price on shares of MannKind from $10.00 to $8.00 and set an "outperform" rating for the company in a research report on Thursday, March 5th. Weiss Ratings lowered MannKind from a "hold (c)" rating to a "sell (d+)" rating in a report on Monday, March 2nd. Finally, Mizuho dropped their target price on MannKind from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Monday, April 13th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.56.

MannKind Stock Down 1.1%

Shares of MNKD opened at $2.71 on Friday. The business's fifty day moving average is $3.15 and its 200 day moving average is $4.73. MannKind has a 12-month low of $2.23 and a 12-month high of $6.51. The stock has a market cap of $836.85 million, a P/E ratio of 135.57 and a beta of 1.04.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.04). MannKind had a net margin of 1.68% and a negative return on equity of 11.21%. The firm had revenue of $111.96 million during the quarter, compared to analyst estimates of $99.85 million. During the same period last year, the business posted $0.03 EPS. The company's revenue was up 45.8% on a year-over-year basis.

Insider Activity

In other news, CEO Michael Castagna acquired 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average price of $2.59 per share, for a total transaction of $259,000.00. Following the completion of the purchase, the chief executive officer owned 2,575,911 shares in the company, valued at approximately $6,671,609.49. This trade represents a 4.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.60% of the stock is currently owned by insiders.

Institutional Trading of MannKind

Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its stake in shares of MannKind by 108.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 2,927 shares during the period. International Assets Investment Management LLC bought a new position in MannKind during the fourth quarter worth about $45,000. Huntington National Bank increased its stake in shares of MannKind by 420.0% in the fourth quarter. Huntington National Bank now owns 10,400 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 8,400 shares in the last quarter. Burkett Financial Services LLC bought a new stake in shares of MannKind in the fourth quarter valued at approximately $59,000. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of MannKind in the fourth quarter valued at approximately $60,000. 49.55% of the stock is currently owned by institutional investors.

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company's core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind's lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.